STDM Overview

Barclays Upgrade: Barclays has upgraded Sartorius AG and Sartorius Stedim Biotech to Overweight, citing a post-COVID recovery in the bioprocessing industry and significant valuation discounts compared to peers, indicating potential for upside as order momentum returns.

Growth Forecasts: Barclays forecasts approximately 12% growth in bioprocess solutions orders for Sartorius in FY25, with overall group sales expected to grow around 7.3%, supported by strong free cash flow generation and improved investor sentiment.

Sartorius' Market Performance: Shares of Sartorius rose 13.4% after the company reaffirmed its full-year guidance despite a 2.0% drop in sales revenue for the first nine months of 2024, indicating strong order intake and demand recovery in the consumables sector.

Challenges and Outlook: The company faces challenges, particularly in its Lab Products & Services division due to weak markets in China, but maintains a robust profitability with an underlying EBITDA margin of 27.7%, expecting to meet its full-year targets.

Goldman Sachs Coverage Initiation: Goldman Sachs has given Sartorius Stedim Biotech a "buy" rating with a 12-month price target of €225, citing its strong position in the bioprocessing market and favorable valuation compared to its parent company, Sartorius AG.

Market Recovery Outlook: Analysts predict a gradual recovery for Sartorius Stedim post-pandemic, with expectations of double-digit revenue growth after 2025, driven by increasing demand for biologic drugs and improvements in operational dynamics.